CAJ | 학술논문

脐带血作为造血干细胞的一大来源，已逐渐获得医学界的认可，随着临床实践的不断展开，对脐带血的使用也趋于标准化。我们通过移植物抗宿主病和治愈情况对骨髓移植与脐带血移植进行了比较，提供了移植用脐带血的择优选取办法及移植的最低细胞剂量，对双份脐带血的选择给出建议，同时对非亲缘脐血与骨髓共输注临床使用情况和嵌合体检测做了介绍与评价。可以看出，在治疗恶性血液病时，脐带血移植是一个可靠的方法。
제대혈작위조혈간세포적일대래원，이축점획득의학계적인가，수착림상실천적불단전개，대제대혈적사용야추우표준화。아문통과이식물항숙주병화치유정황대골수이식여제대혈이식진행료비교，제공료이식용제대혈적택우선취판법급이식적최저세포제량，대쌍빈제대혈적선택급출건의，동시대비친연제혈여골수공수주림상사용정황화감합체검측주료개소여평개。가이간출，재치료악성혈액병시，제대혈이식시일개가고적방법。
Recent large international studies suggested that allogeneic umbilical cord blood(UCB) transplantation may potentially emerge as the frontline stem cell source for patients with hematopoietic malignancies because of its ability to confer superior overall and relapse-free survival compared with matched marrow stem cells. In this ar-ticle we showed graft-versus-host disease and survival rate of bone marrow transplantation compare with the UCB transplantation(UCBT) and offered a priority principle for UCB taking; the minimum cell dose for UCBT, when double UCB is supposed to take and chimera detection. So we suggest UCBT is a reliable way to the patients.